reports
Unimed: 1 director
A director at Unimed bought 11,268 shares at 7.180TND and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
A stagnation of the local activity
During Q2 2016, Unimed’s sales increased by 11.4% to TND16.98m against TND15.24m in Q2 2015. This growth has been pulled up by Pharmaceutical sales (+10.5% yoy), Export sales (+34.5% yoy) as well as export outsourcing (+13.2% yoy). Thus, the company’s revenues in H1 2016 reached TND31.79m, an increase of 6.3% compared to H1 2015. This growth has been slowed down by Hospitals sales which declined by 5.3% to TND10.03m. The production volume rose by only 1.2% to 89.9 million units.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.